Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1996 Apr 30;93(9):4498–4503. doi: 10.1073/pnas.93.9.4498

Normal human serum contains a natural IgM antibody cytotoxic for human neuroblastoma cells.

M W Ollert 1, K David 1, C Schmitt 1, A Hauenschild 1, R Bredehorst 1, R Erttmann 1, C W Vogel 1
PMCID: PMC39567  PMID: 8633097

Abstract

Neuroblastoma (NB) is characterized by the second highest spontaneous regression of any human malignant disorder, a phenomenon that remains to be elucidated. In this study, a survey of 94 normal human adult sera revealed a considerable natural humoral cytotoxicity against human NB cell lines in approximately one-third of the tested sera of both genders. Specific cell killing by these sera was in the range of 40% to 95%. Serum cytotoxicity was dependent on an intact classical pathway of complement. By several lines of evidence, IgM antibodies were identified as the cytotoxic factor in the sera. Further analyses revealed that a 260-kDa protein was recognized by natural IgM of cytotoxic sera in Western blots of NB cell extracts. The antigen was expressed on the surface of seven human NB cell lines but not on human melanoma or other control tumor cell lines derived from kidney, pancreas, colon, bone, skeletal muscle, lymphatic system, and bone marrow. Furthermore, no reactivity was observed with normal human fibroblasts, melanocytes, and epidermal keratinocytes. The antigen was expressed in vivo as detected by immunohistochemistry in both the tumor of a NB patient and NB tumors established in nude rats from human NB cell lines. Most interestingly, the IgM anti-NB antibody was absent from the sera of 11 human NB patients with active disease. The anti-NB IgM also could not be detected in tumor tissue obtained from a NB patient. Collectively, our data suggest the existence of a natural humoral immunological tumor defense mechanism, which could account for the in vivo phenomenon of spontaneous NB tumor regression.

Full text

PDF
4498

Images in this article

4499Fig. 1
on p.4499
4501Fig. 3
on p.4501
4501Fig. 4
on p.4501
4501Fig. 5
on p.4501
4501Fig. 6
on p.4501

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Avrameas S. Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. Immunol Today. 1991 May;12(5):154–159. doi: 10.1016/S0167-5699(05)80045-3. [DOI] [PubMed] [Google Scholar]
  2. BECKWITH J. B., PERRIN E. V. IN SITU NEUROBLASTOMAS: A CONTRIBUTION TO THE NATURAL HISTORY OF NEURAL CREST TUMORS. Am J Pathol. 1963 Dec;43:1089–1104. [PMC free article] [PubMed] [Google Scholar]
  3. Bolande R. P., Mayer D. C. The cytolysis of human neuroblastoma cells by a natural IgM 'antibody'-complement system in pregnancy serum. Cancer Invest. 1990;8(6):603–611. doi: 10.3109/07357909009018927. [DOI] [PubMed] [Google Scholar]
  4. Bosslet K., Mennel H. D., Rodden F., Bauer B. L., Wagner F., Altmannsberger A., Sedlacek H. H., Wiegandt H. Monoclonal antibodies against epitopes on ganglioside GD2 and its lactones. Markers for gliomas and neuroblastomas. Cancer Immunol Immunother. 1989;29(3):171–178. doi: 10.1007/BF00199992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brodeur G. M., Moley J. F. Biology of tumors of the peripheral nervous system. Cancer Metastasis Rev. 1991 Dec;10(4):321–333. doi: 10.1007/BF00554794. [DOI] [PubMed] [Google Scholar]
  6. Cheung N. K., Saarinen U. M., Neely J. E., Landmeier B., Donovan D., Coccia P. F. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res. 1985 Jun;45(6):2642–2649. [PubMed] [Google Scholar]
  7. Chilosi M., Pizzolo G., Vincenzi C. Haematoxylin counterstaining of immunofluorescence preparations. J Clin Pathol. 1983 Jan;36(1):114–115. doi: 10.1136/jcp.36.1.114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Galili U. Interaction of the natural anti-Gal antibody with alpha-galactosyl epitopes: a major obstacle for xenotransplantation in humans. Immunol Today. 1993 Oct;14(10):480–482. doi: 10.1016/0167-5699(93)90261-i. [DOI] [PubMed] [Google Scholar]
  9. Hanada M., Krajewski S., Tanaka S., Cazals-Hatem D., Spengler B. A., Ross R. A., Biedler J. L., Reed J. C. Regulation of Bcl-2 oncoprotein levels with differentiation of human neuroblastoma cells. Cancer Res. 1993 Oct 15;53(20):4978–4986. [PubMed] [Google Scholar]
  10. Hellström I. E., Hellström K. E., Pierce G. E., Bill A. H. Demonstration of cell-bound and humoral immunity against neuroblastoma cells. Proc Natl Acad Sci U S A. 1968 Aug;60(4):1231–1238. doi: 10.1073/pnas.60.4.1231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hellström K. E., Hellström I. Spontaneous tumor regression: possible relationship to in vitro parameters of tumor immunity. Natl Cancer Inst Monogr. 1976 Nov;44:131–134. [PubMed] [Google Scholar]
  12. Juhl H., Petrella E. C., Cheung N. K., Bredehorst R., Vogel C. W. Complement killing of human neuroblastoma cells: a cytotoxic monoclonal antibody and its F(ab')2-cobra venom factor conjugate are equally cytotoxic. Mol Immunol. 1990 Oct;27(10):957–964. doi: 10.1016/0161-5890(90)90118-j. [DOI] [PubMed] [Google Scholar]
  13. Kalthoff H., Roeder C., Gieseking J., Humburg I., Schmiegel W. Inverse regulation of human ERBB2 and epidermal growth factor receptors by tumor necrosis factor alpha. Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):8972–8976. doi: 10.1073/pnas.90.19.8972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kipps T. J. The CD5 B cell. Adv Immunol. 1989;47:117–185. doi: 10.1016/s0065-2776(08)60663-x. [DOI] [PubMed] [Google Scholar]
  15. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  16. Natoli E. J., Jr, Livingston P. O., Pukel C. S., Lloyd K. O., Wiegandt H., Szalay J., Oettgen H. F., Old L. J. A murine monoclonal antibody detecting N-acetyl- and N-glycolyl-GM2: characterization of cell surface reactivity. Cancer Res. 1986 Aug;46(8):4116–4120. [PubMed] [Google Scholar]
  17. Noguchi P., Wallace R., Johnson J., Earley E. M., O'Brien S., Ferrone S., Pellegrino M. A., Milstien J., Needy C., Browne W. Characterization of the WIDR: a human colon carcinoma cell line. In Vitro. 1979 Jun;15(6):401–408. doi: 10.1007/BF02618407. [DOI] [PubMed] [Google Scholar]
  18. Ollert M. W., Calderone R. A. A monoclonal antibody that defines a surface antigen on Candida albicans hyphae cross-reacts with yeast cell protoplasts. Infect Immun. 1990 Mar;58(3):625–631. doi: 10.1128/iai.58.3.625-631.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Ollert M. W., Frade R., Fiandino A., Panneerselvam M., Petrella E. C., Barel M., Pangburn M. K., Bredehorst R., Vogel C. W. C3-cleaving membrane proteinase. A new complement regulatory protein of human melanoma cells. J Immunol. 1990 May 15;144(10):3862–3867. [PubMed] [Google Scholar]
  20. Ollert M. W., Kadlec J. V., David K., Petrella E. C., Bredehorst R., Vogel C. W. Antibody-mediated complement activation on nucleated cells. A quantitative analysis of the individual reaction steps. J Immunol. 1994 Sep 1;153(5):2213–2221. [PubMed] [Google Scholar]
  21. Ollert M. W., Kadlec J. V., Petrella E. C., Bredehorst R., Vogel C. W. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65. Cancer Res. 1993 Feb 1;53(3):592–599. [PubMed] [Google Scholar]
  22. Patterson B. K., Till M., Otto P., Goolsby C., Furtado M. R., McBride L. J., Wolinsky S. M. Detection of HIV-1 DNA and messenger RNA in individual cells by PCR-driven in situ hybridization and flow cytometry. Science. 1993 May 14;260(5110):976–979. doi: 10.1126/science.8493534. [DOI] [PubMed] [Google Scholar]
  23. Reynolds J. V., Shou J., Choi H., Sigal R., Ziegler M. M., Daly J. M. The influence of natural killer cells in neuroblastoma. Arch Surg. 1989 Feb;124(2):235–239. doi: 10.1001/archsurg.1989.01410020109018. [DOI] [PubMed] [Google Scholar]
  24. Schulz G., Bumol T. F., Reisfeld R. A. Monoclonal antibody-directed effector cells selectively lyse human melanoma cells in vitro and in vivo. Proc Natl Acad Sci U S A. 1983 Sep;80(17):5407–5411. doi: 10.1073/pnas.80.17.5407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Thornton B. P., Vetvicka V., Ross G. D. Natural antibody and complement-mediated antigen processing and presentation by B lymphocytes. J Immunol. 1994 Feb 15;152(4):1727–1737. [PubMed] [Google Scholar]
  26. Ueda R., Shiku H., Pfreundschuh M., Takahashi T., Li L. T., Whitmore W. F., Oettgen H. F., Old L. J. Cell surface antigens of human renal cancer defined by autologous typing. J Exp Med. 1979 Sep 19;150(3):564–579. doi: 10.1084/jem.150.3.564. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Vogel C. W., Müller-Eberhard H. J. Cobra venom factor: improved method for purification and biochemical characterization. J Immunol Methods. 1984 Oct 12;73(1):203–220. doi: 10.1016/0022-1759(84)90045-0. [DOI] [PubMed] [Google Scholar]
  28. Winand R. J., Devigne J. W., Meurisse M., Galili U. Specific stimulation of Graves' disease thyrocytes by the natural anti-Gal antibody from normal and autologous serum. J Immunol. 1994 Aug 1;153(3):1386–1395. [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES